Securities code: Fujian Cosunter Pharmaceutical Co.Ltd(300436) securities abbreviation: Fujian Cosunter Pharmaceutical Co.Ltd(300436) Announcement No.: 2022049 Fujian Cosunter Pharmaceutical Co.Ltd(300436)
First quarter report 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions. Important content tips: 1. The board of directors, the board of supervisors, directors, supervisors and senior managers guarantee that the quarterly report is true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2. The person in charge of the company, the person in charge of accounting and the person in charge of the accounting organization (Accounting Supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report. 3. Whether the first quarter report has been audited □ yes √ No 1. Main financial data (I) whether the company needs to retroactively adjust or restate the accounting data of previous years □ yes √ no
Increase or decrease in the reporting period compared with the same period of the previous year
Operating income (yuan): 96523364679492959185 1.68%
Net profit attributable to shareholders of listed company (yuan) -913162917177005255 -615.90%
Net profit attributable to shareholders of listed companies after deducting non recurring profit and loss of -1157564953 -98438215 -107593% (yuan)
Net cash flow from operating activities (yuan) -1932817043311890002 -719.71%
Basic earnings per share (yuan / share) -0.0575 0.0126 -556.35%
Diluted earnings per share (yuan / share) -0.0575 0.0126 -556.35%
Weighted average return on net assets -0.88%, 0.31% - 1.19%
Increase or decrease at the end of the reporting period compared with the end of the previous year
Total assets (yuan): 1493133337225144676652034 3.20%
Owner's equity attributable to shareholders of the listed company 103422342847104335505764 -0.88% (yuan)
（2） Non recurring profit and loss items and amount √ applicable □ not applicable
Unit: Yuan
Description of the amount of the project in the current reporting period
Government subsidies included in current profits and losses (closely related to the company's normal business, in line with national 304578631)
(except for government subsidies that are continuously enjoyed according to certain standards, quotas or quotas as stipulated by the national policy)
Other non operating income and expenditure other than the above -7985148
Less: income tax impact 44186976
Influence amount of minority shareholders' equity (after tax) 8004471
Total 244402036--
Details of other profit and loss items that meet the definition of non recurring profit and loss: □ applicable √ not applicable. The company does not have details of other profit and loss items that meet the definition of non recurring profit and loss. Description of defining the non recurring profit and loss items listed in the explanatory announcement on information disclosure of companies offering securities to the public No. 1 - non recurring profit and loss as recurring profit and loss items □ applicable √ not applicable the company does not define the non recurring profit and loss items listed in the explanatory announcement on Information Disclosure of companies offering securities to the public No. 1 - non recurring profit and loss as recurring profit and loss items. （3） Changes and reasons of main accounting data and financial indicators √ applicable □ not applicable
During the reporting period, the company achieved a total operating income of 965234 million yuan, an increase of 1.68% year-on-year, and a net profit loss attributable to shareholders of listed companies of 9.1316 million yuan, a significant decrease year-on-year. The main reasons are as follows:
1. During the reporting period, the company continued to invest in R & D and unswervingly promoted the R & D of multiple global class I innovative drugs. The R & D cost was 25.841 million yuan, an increase of 100532 million yuan year-on-year, an increase of 63.68%;
2, during the reporting period, affected by the epidemic, joint venture company Fujian Boao medical laboratory Co., Ltd. New Coronavirus detection business increased significantly, the company's investment income calculated by equity method increased accordingly.
Changes in other major accounting data and financial indicators are shown in the following table:
Balance sheet items closing balance increase / decrease proportion of closing balance of last period reason for increase / decrease
Notes receivable 314055911201989946112065965 55.48% increase in the amount settled by bank acceptance bills in the reporting period
It is mainly due to the increase of 18.82% profit from the long-term equity investment of the associate company Fujian Boao in the current period, which is 1187902023299977 Foran Energy Group Co.Ltd(002911) 881319941. The company adopts the equity method to calculate the investment income
The construction in progress is 18583268352147221605703861107782, which is mainly an increase of 26.23% in the integrated construction of API preparation I of the project invested by raising funds in this phase
Long term deferred expenses 1024366393727686346296680047 40.77% are mainly transferred into long-term deferred expenses accounting after the relocation of power lines in the plant area
Short term borrowings 1109408555077755337593318551791 42.68% due to the increase of borrowings in the current period
Payroll payable 4470916841058957042 - 611865358 - 57.78% final award at the end of last year paid in this period
Other current liabilities 1147965007489625539900245 due to 53.27% increase in advance receipts
The parent company contributes deferred income tax liabilities with intangible assets and monetary funds 829659902204877302624782600 to establish Guangsheng Zhonglin, a subsidiary of innovative medicine holding, and 304.95% of the taxable income is reported for income tax in two periods to confirm the deferred liabilities
Minority shareholders' equity 29634544416488558532314598588 due to 356.72% of minority shareholders' investment in Guangsheng Zhonglin, a holding subsidiary
Increase / decrease proportion of current period amount of income statement items in the same period of last year increase / decrease reason
Taxes and surcharges 22578255515990064265881913 41.20% the increase of turnover tax in the reporting period led to the increase of surcharges
During the reporting period, innovative drugs added New Coronavirus R & D costs 2584097881, 1578773436, 1005324445, 63.68%, small molecule oral innovative medicine GST-HG171 project, and the total cost of research and development of new drugs was 22 million 292 thousand and 300 yuan during the reporting period.
The financial expenses were 54839268, 215820560 - 160981292 - 74.59%, mainly due to the increase of interest income of the company's raised funds
Mainly due to the impact of the epidemic, the investment income of the associated company Fujian 1881319941904152702977167239 the covid-19 test business of Boao medical laboratory Co., Ltd. increased significantly, and the investment income calculated by the equity method of the company increased accordingly
Reasons for the increase or decrease of the amount in the current period and the amount in the same period of last year in the cash flow statement
- 19328170433118 from operating activities,
